randomized clinical trials

Related by string. Randomized Clinical Trial * Randomized . randomizing . randomizer : randomized controlled trial . randomized controlled trials . randomized placebo controlled / clinicals . CLINICAL . Clinicals : Phase III clinical trials . Phase III clinical . Phase 2b clinical / trialed . trialing . Trial : Week Premium Trial . Phase III trials . placebo controlled clinical trials * *

Related by context. All words. (Click for frequent words.) 85 randomized trials 82 randomized controlled trials 77 randomized controlled clinical trials 76 meta analyzes 76 placebo controlled trials 73 placebo controlled studies 72 randomized clinical 71 observational studies 71 RCTs 70 meta analysis 70 randomized controlled 69 randomized controlled trial 67 placebo controlled clinical trials 67 prospective randomized 67 randomized controlled trials RCTs 66 subgroup analyzes 66 multicenter trials 66 multicenter 66 randomized placebo controlled 66 clinical trials 65 nonrandomized 65 placebo controlled 65 epidemiological studies 65 trials RCTs 64 multicenter study 64 clinical trial 64 randomized controlled clinical 63 prospective randomized controlled 63 RE LY 63 epidemiologic studies 63 placebo controlled clinical 62 observational study 62 Phase III trials 62 multicenter randomized 62 statin therapy 62 prospective observational 62 lipid lowering therapy 62 randomized 62 active comparator 61 randomized Phase III 61 ExTRACT TIMI 61 SPIRIT IV 61 UKPDS 61 ALLHAT 61 antihypertensive drugs 61 ticagrelor 60 fluvastatin 60 placebo controlled Phase 60 blinded randomized controlled 60 randomized multicenter 60 HCV SPRINT 60 longitudinal studies 60 double blinded randomized 60 randomized multicenter trial 60 viral kinetic 60 antiplatelet agents 60 phase IIIb 60 DAPT 60 statins 60 clinical pharmacology studies 60 paclitaxel eluting stents 60 multicentre 59 RE LY ® 59 randomized blinded 59 rosuvastatin 59 placebo controlled randomized 59 double blind placebo 59 BARI 2D 59 efficacy 59 postmenopausal women 59 dose regimens 59 multicenter clinical 59 phase IIb clinical 59 prospective observational studies 59 antihypertensive therapy 59 IMPROVE HF 59 SPIRIT III 59 Meta analyzes 59 subanalysis 59 multicentre randomized 59 Clinical trials 58 VADT 58 bendamustine 58 Phase 2b study 58 HORIZONS AMI trial 58 rivaroxaban 58 evaluating REVLIMID 58 phase IIb 58 blind randomized 58 antihypertensive medications 58 Stenting Trial CREST 58 AIM HIGH 58 chemoradiotherapy 58 APPRAISE 58 teriflunomide 58 HIVNET 58 confirmatory clinical 58 olaparib 58 hypertensive patients 58 selenium supplementation 58 statin 58 pharmacokinetic studies 58 NO# [002] 58 substudy 58 Phase IIb trial 58 ACUITY trial 58 phase IIb trial 58 metaanalysis 58 dosage regimens 58 noninferiority 58 atorvastatin Lipitor 58 dose escalation 58 Phase 2a trial 58 lipid lowering drugs 58 riociguat 58 IMPROVE IT 58 ENDEAVOR IV 58 carotid stents 58 randomized double 58 sorafenib Nexavar 58 phase IIa 58 HPTN 57 nesiritide 57 AVERROES 57 multicenter prospective 57 vitamin D supplementation 57 thrombolytic therapy 57 neratinib 57 eprotirome 57 EVEREST II 57 prospective randomized placebo 57 MERLIN TIMI 57 TAXUS VI 57 NATRECOR ® 57 phase Ib 57 neoadjuvant 57 β blockers 57 prospective cohort 57 studies 57 eptifibatide 57 celecoxib 57 drug eluting stents 57 hemodialysis patients 57 unblinded 57 placebo controlled Phase III 57 prospective multicenter 57 bevacizumab Avastin 57 ONTARGET 57 superficial bladder cancer 57 antithrombotic therapy 57 Clinical Antipsychotic Trials 57 chemotherapeutic regimens 57 ATACAND 57 sunitinib malate 57 cilostazol 57 antiplatelet therapy 57 CYPHER R Sirolimus eluting 57 nab paclitaxel 57 ASCEND HF 57 Val HeFT 57 CYPHER Stent 57 tolerability 56 pioglitazone 56 liver transplant recipients 56 Edge STudy 56 darunavir ritonavir 56 multicenter Phase II 56 dosing regimens 56 SCD HeFT 56 MADIT CRT trial 56 Randomized trials 56 ENDEAVOR clinical 56 rosiglitazone 56 analgesic efficacy 56 CYPHER ® Stent 56 efficacy endpoints 56 GnRH agonists 56 COPAXONE R 56 MADIT CRT 56 HCV RESPOND 2 56 pazopanib 56 blinded placebo controlled 56 rFVIIa 56 Phase 1b trial 56 RE LY trial 56 rt PA 56 pioglitazone Actos 56 valsartan 56 retrospective cohort 56 temsirolimus 56 candesartan 56 monotherapy 56 antihypertensive agents 56 CALGB 56 blind randomized placebo 56 beta blocker therapy 56 double blinded placebo 56 tibolone 56 Protelos 56 multicenter Phase III 56 DSMB 56 mycophenolate mofetil 56 telcagepant 56 tolvaptan 56 viral kinetics 56 clinically meaningful 56 mg dose 56 HeFT 56 MADIT II 56 SPARCL 56 phase IIa clinical 56 Subgroup analyzes 56 BoNTA 56 carotid artery stenting 56 fondaparinux 56 bronchial thermoplasty 56 Phase IIB 56 lanthanum carbonate 56 TRITON TIMI 56 antiplatelet drugs 56 oral rivaroxaban 56 CYPHER ® Sirolimus eluting 55 ACCORD Lipid 55 glucose lowering 55 PRECiSE 55 multicenter clinical trials 55 LibiGel Phase III 55 adjuvant therapy 55 prospectively defined 55 masked placebo controlled 55 anti leukemic 55 LUX Lung 55 INTERHEART study 55 NSABP B 55 patients undergoing percutaneous 55 PROactive study 55 NATRECOR R 55 topical NSAIDs 55 multicenter Phase 55 glitazones 55 deferiprone 55 ADVANCE PD 55 carotid stenting 55 FOSRENOL R 55 ARCOXIA 55 Phase IIIb study 55 Carotid Revascularization Endarterectomy vs. 55 controlled multicenter 55 adalimumab 55 cardiovascular morbidity 55 Intervention Effectiveness 55 oral FTY# 55 PROSTVAC TM 55 calcium supplementation 55 preclinical efficacy 55 vitro studies 55 CARE HF 55 tamoxifen therapy 55 abatacept 55 phosphate binders 55 multicentre study 55 olmesartan 55 NEVO RES 55 retrospective cohort study 55 Mylotarg 55 antioxidant supplements 55 unfractionated heparin 55 oral bisphosphonates 55 Phase III randomized 55 BCIRG 55 tolerability profile 55 randomized multicenter Phase III 55 multicenter placebo controlled 55 warfarin therapy 55 Doxil ® 55 salsalate 55 dose statin therapy 55 teriparatide 55 HyQ 55 bioabsorbable stent 55 Cochrane Systematic Review 55 PREZISTA r 55 SYNTAX trial 55 inhibitor RG# 55 NICE SUGAR 55 dose escalation Phase 55 anastrozole 55 everolimus eluting stent 55 azacitidine 55 HORIZONS AMI 55 paricalcitol 55 trabectedin 55 SWOG 55 tiotropium 55 lacosamide 55 nonrandomized studies 54 TAXUS stent 54 iniparib 54 rosuvastatin Crestor 54 Phase #/#a 54 APTIVUS r 54 premenopausal women 54 HOPE TOO 54 EURIDIS 54 prucalopride 54 oral Xeloda 54 intravenous bisphosphonates 54 CAMMS# 54 retrospective observational study 54 TAXUS ATLAS 54 infantile colic 54 recurrent GBM 54 NCCTG N# 54 canakinumab 54 dabigatran etexilate 54 CYPHER R Stent 54 APTIVUS 54 strontium ranelate 54 Proellex TM 54 phase IIb study 54 ACOSOG Z# 54 ELCAP 54 inhaled corticosteroids 54 clinical endpoints 54 candesartan cilexetil 54 aripiprazole Abilify 54 label multicenter Phase 54 EchoCRT 54 metastatic RCC 54 aldosterone antagonists 54 Randomized controlled 54 SABCS 54 inhaled anticholinergics 54 Allovectin 7 ® 54 multicenter randomized placebo controlled 54 Prostate Cancer Prevention 54 surrogate endpoint 54 thiazide diuretics 54 eplerenone 54 direct thrombin inhibitors 54 adjuvant chemotherapy 54 prospective multicentre 54 PRIMO CABG2 54 prospective nonrandomized 54 aldosterone antagonist 54 oral ridaforolimus 54 risperidone Risperdal 54 CLARITY study 54 stable angina 54 enzastaurin 54 eltrombopag 54 prespecified 54 insulin glargine 54 glatiramer acetate 54 heavily pretreated patients 54 SYNTAX 54 AIR2 Trial 54 prospective observational cohort 54 thromboprophylaxis 54 secondary efficacy endpoints 54 lipid lowering agents 54 antiepileptics 54 RRMS patients 54 post hoc 54 PRoFESS 54 multicenter randomized double 54 lamotrigine 54 SORT OUT III 54 pharmacodynamics 54 pitavastatin 54 Health Initiative WHI 54 Observational studies 54 DU #b 54 BRAF inhibitor 54 vicriviroc 54 statin medications 54 androgen suppression 54 preoperative chemotherapy 54 montelukast 54 Phase IIb 54 protease inhibitor PI 54 dosing cohorts 54 ARIXTRA 54 LDL lowering 54 blind randomized controlled 54 letrozole 54 allopurinol 54 AZILECT R 54 hemostatic efficacy 54 prospective longitudinal 54 ENDEAVOR II 54 sunitinib 54 longitudinal cohort study 54 Ophena 54 everolimus eluting stents 54 vertebroplasty 54 ROCKET AF 54 ezetimibe simvastatin 54 multicenter phase 54 ixabepilone 54 Digital Mammographic Imaging 54 APPROVe 54 postmarketing surveillance 54 Phase 2b 54 VTE prophylaxis 54 multicenter randomized controlled 54 cediranib 54 blinded randomized 54 Phase Ib clinical 54 CANCIDAS 54 Endeavor stent 54 tocilizumab 54 bosentan 54 zotarolimus eluting stent 54 KRN# 54 BOLDER II 54 glargine 54 pharmacokinetic pharmacodynamic 54 dual antiplatelet therapy 53 blind placebo controlled 53 elective PCI 53 CRESTOR #mg 53 endometrial hyperplasia 53 ADAGIO study 53 dosing schedules 53 antithrombotic 53 Systematic reviews 53 Rosuvastatin 53 dose clopidogrel 53 coronary interventions 53 Phase Ib 53 composite endpoint 53 tipranavir 53 concomitant medications 53 cangrelor 53 coronary intervention 53 tamsulosin 53 Amrubicin 53 BRIM3 53 KRAS status 53 testosterone supplementation 53 pharmacodynamic 53 Phase IIIb 53 axitinib 53 postmenopausal hormone therapy 53 blind multicenter 53 PERSEUS 53 antiplatelet therapies 53 randomized Phase 53 SYMBICORT 53 Betaferon ® 53 Cochrane reviewers 53 anti arrhythmic drug 53 pharmacokinetic 53 diuretic chlorthalidone 53 Intervention Effectiveness CATIE 53 Ophena TM 53 NeuroStar TMS Therapy 53 Intervention Trial GAIT 53 pre menopausal 53 CLBP 53 meta analysis pooling 53 chemoprevention trials 53 OHR/AVR# 53 HAART regimens 53 COREG 53 AEGR 53 pharmacokinetic PK 53 prospective randomized multicenter 53 optimal dosing 53 CHARISMA trial 53 belatacept 53 colorectal liver metastases 53 blinded randomized placebo controlled 53 EQUIP OB 53 efficacy endpoint 53 posaconazole 53 nonclinical studies 53 antiepileptic drugs 53 Prostate AdenoCarcinoma Treatment 53 non inferiority 53 antidiabetic drugs 53 telmisartan 53 KRAS variant 53 Aptivus 53 randomized Phase IIb 53 symptomatic BPH 53 ritonavir boosted 53 hydroxychloroquine 53 Clinical Outcomes Utilizing Revascularization 53 pharmacological interventions 53 prospectively randomized 53 SCH # 53 oncologic outcomes 53 rosiglitazone Avandia 53 mg administered orally 53 MMP inhibitors 53 TAXUS Stent 53 Xanafide 53 Novartis Zometa 53 phase 2a 53 ruboxistaurin 53 multicenter multinational 53 relapsed MM 53 thromboembolic events 53 peginterferon alfa 2b 53 PFO closure 53 nebulized formoterol fumarate 53 transcatheter aortic valve implantation 53 antitumor effect 53 fibrates 53 pivotal bioequivalence 53 rALLy trial 53 ECASS 53 chemoradiation 53 pertuzumab 53 Combination therapy 53 efficacy tolerability 53 fibrate 53 levosimendan 53 Dabigatran 53 Communities ARIC study 53 adjuvant radiotherapy 53 generalizability 53 DCCT 53 dose cohorts 53 bisphosphonate therapy 53 recurrent malignant glioma 53 visilizumab 53 dietary questionnaires 53 paclitaxel eluting stent 53 MIRAPEX 53 Cholesterol Levels SPARCL 53 RoACTEMRA 53 Xelox 53 antithrombotics 53 dose regimen 53 symptomatic VTE 53 AVADO 53 tamoxifen 53 ARB telmisartan 53 thiazolidinediones 53 randomized multicentre 53 pegylated liposomal doxorubicin 53 CYPHER R stent 53 TAXUS Liberte Stent 53 aliskiren 53 salmeterol fluticasone 53 Phase IIa trial 53 paliperidone ER 53 Pemetrexed 53 RTOG 53 PRE SURGE 53 carcinogenicity studies 53 ACCORD 53 TAXUS IV 53 idraparinux 53 standard chemotherapy regimen 53 VFEND 53 docetaxel chemotherapy 53 Taxus Stent 53 PREVENT IV 53 Sunitinib 53 clevidipine 53 newer antipsychotics 53 Phase 2b clinical 53 angiotensin receptor blocker ARB 53 EFAPROXYN 53 Carfilzomib 53 basal bolus regimen 53 ivabradine 53 TMC# C# 53 STRIDE PD 53 oral antiplatelet 53 sirolimus 53 Microplasmin 53 clopidogrel 53 AIR CF1 53 preclinical studies 53 methodologically rigorous 53 Medicine NEJM 53 Phase III clinical trials 52 postmenopausal 52 Atacand 52 PLCO 52 Multiethnic Study 52 carvedilol 52 #mg dose [003] 52 darunavir 52 perindopril 52 Prospective Randomized 52 HMG CoA reductase inhibitors 52 Ovarian PLCO Cancer 52 GP IIb IIIa inhibitors 52 clinical 52 antiepileptic drugs AEDs 52 Phase III placebo controlled 52 Women Ischemia Syndrome 52 afatinib 52 sirolimus eluting stents 52 Perforomist Inhalation Solution 52 Prostate Lung Colorectal 52 Lipid Lowering Treatment 52 fenofibrate 52 intravenous cyclophosphamide 52 Evaluation WISE 52 pharmacokinetic characteristics 52 fenretinide 52 metreleptin 52 dose titration 52 anacetrapib 52 Study AREDS 52 Phase 1b clinical 52 neoadjuvant treatment 52 RSD# oral 52 QTc prolongation 52 non selective NSAIDs 52 NOXAFIL 52 oral diclofenac 52 endarterectomy 52 Celebrex celecoxib 52 NSTE ACS 52 multicentre randomized double 52 Phase III randomized controlled 52 thoracoscopic lobectomy 52 GAMMAGARD 52 DASISION 52 irbesartan 52 Pharmacokinetic 52 undergone radical prostatectomy 52 lasofoxifene 52 ISIS # 52 Phase III clinical 52 nondiabetic patients 52 lymphadenectomy 52 Xinlay 52 pregabalin 52 ToGA 52 velafermin 52 Randomized 52 #F FDG PET 52 Torisel 52 prasugrel Effient 52 statistical significance 52 immunosuppressive regimens 52 AVANDIA 52 TAXUS 52 Valsartan 52 observational cohort 52 insulin detemir 52 PICSO ® 52 ABSORB trial 52 Tolvaptan 52 MAGE A3 ASCI 52 Phase Ib study 52 Percutaneous Coronary Intervention 52 infliximab Remicade 52 oral antidiabetic agents 52 Genous stent 52 ConclusionThis 52 arzoxifene 52 ximelagatran 52 inhaled steroids 52 Screening Trial 52 FOLPI 52 ezetimibe 52 coronary angiography 52 renal tumors 52 sorafenib 52 FASLODEX 52 BETAS 52 Phase 2a clinical 52 Dialysis Outcomes 52 alpha blocker 52 ascending dose 52 urate lowering 52 Inegy 52 Phase Ib II 52 DMARD 52 secretin 52 Zilver PTX 52 tolerability profiles 52 Committee IDMC 52 atherothrombotic events 52 Xyotax 52 INCB# [003] 52 BRIM2 52 LMWH 52 tumor shrinkage 52 psychodynamic psychotherapy 52 randomized controlled Phase 52 AVOREN 52 antiepileptic drug 52 Candesartan 52 ganetespib 52 dietary modification 52 Phase IIIb clinical 52 vitro experiments 52 ONGLYZA 52 noninferior 52 INC# 52 BAY #-# 52 Randomized Clinical Trial 52 ORMD 52 CURRENT OASIS 7 52 LY# [003] 52 Nesiritide 52 TACE 52 darapladib 52 AIR CF2 52 NovoTTF 52 Clopidogrel 52 exemestane 52 genotypic resistance 52 Afatinib 52 intensive statin therapy 52 elotuzumab 52 macrovascular disease 52 anti angiogenic therapy 52 anti arrhythmic 52 lumiracoxib 52 crizotinib PF # 52 aprotinin 52 RECORD1 52 breast cancer recurrences 52 Adlea 52 Femara letrozole 52 dexpramipexole 52 anakinra 52 CALGB # [002] 52 #mg dose [001] 52 statin simvastatin 52 SYMMETRY trial 52 PFO migraine 52 HIV HCV coinfected 52 valproate 52 refractory CLL 52 pegylated interferon 52 IVIg 52 standard chemotherapy regimens 52 pomalidomide 52 lipid lowering 52 liver biopsies 52 dutasteride 52 CHAMPION PCI 52 Rasilez Tekturna 52 relapsed myeloma 52 angiographic outcomes 52 methodological limitations 52 methotrexate therapy 52 antidepressant efficacy 52 Tekamlo 52 multicenter randomized clinical 52 Rivaroxaban 52 antiretroviral regimens 52 lipid parameters 52 LATUDA 52 transurethral resection 52 Multicenter 52 pharmacologic treatments 52 BOLDER 52 coxib 52 clinically meaningful differences 52 chlorthalidone 52 pulmonary toxicity 52 NSABP 52 cholinesterase inhibitors 52 antibiotic prophylaxis 52 doxorubicin docetaxel 52 virologic response 52 calcineurin inhibitors 52 pegylated interferon alfa 2b 52 mg doses 52 Phase III VISTA 52 dose escalation trial 52 guggul 52 dose escalation clinical 52 metastatic HRPC 52 AZILECT ® 52 midstage clinical trials 52 dacarbazine chemotherapy 52 CRLX# 52 NSAID 52 elagolix 52 Crestor rosuvastatin 52 alvimopan 52 trastuzumab Herceptin ® 52 tigecycline 52 ACTEMRA TM 52 ataluren 52 clinically relevant 52 olanzapine Zyprexa 52 Epidemiologic studies 52 Screening Trial DMIST 52 PRADAXA 52 Remifemin 52 Pharmacokinetic studies 52 tolevamer 52 atypicals 52 NNRTI resistance 51 aripiprazole 51 olanzapine LAI 51 octreotide 51 post menopausal 51 carotid artery stenting CAS 51 abciximab 51 cardioprotective effects 51 NEJM 51 newer atypical antipsychotics 51 Thrombolysis 51 febuxostat 51 caspofungin 51 XIENCE V demonstrated 51 ß blockers 51 antibiotic regimens 51 bexarotene 51 peg interferon 51 raltegravir 51 PRECISE 51 NEVO ™ 51 LCP AtorFen 51 iPrEx 51 rivaroxaban Xarelto 51 RAPAFLO R 51 atrasentan 51 PROMUS Element Stent 51 carotid endarterectomy 51 FOSRENOL ® 51 coronary revascularization 51 recurrent ovarian cancer 51 PSN# [002] 51 conventional angiography 51 aromatase inhibitor 51 vorinostat 51 desmoteplase 51 PEGylated interferon beta 1a 51 pharmacokinetics PK 51 Navelbine ® 51 milligram doses 51 leucovorin 51 landmark ATHENA 51 ELACYT 51 reinfarction 51 Board DSMB 51 NSAIDs 51 number NCT# ClinicalTrials.gov 51 ancrod 51 chemotherapy gemcitabine 51 myocardial infarctions MIs 51 therapeutic regimens 51 antithrombotic agents 51 tecarfarin 51 ProSavin 51 REALITY Trial 51 relapsed SCLC 51 label multicenter 51 ZoMaxx 51 dabigatran 51 tricyclic antidepressants 51 lomitapide 51 antihypertensives 51 midstage studies 51 Zoraxel 51 bolus dose 51 maximally tolerated dose 51 ginkgo extract 51 Cloretazine 51 Xience V stent 51 ThermoDox R 51 XL# SAR# 51 dosing cohort 51 TRANSFORMS 51 pharmacokinetics pharmacodynamics 51 aspirin clopidogrel 51 patients undergoing CABG 51 ENHANCE trial 51 vildagliptin 51 QNEXA 51 COPAXONE ® 51 LEXIVA r 51 FDG PET 51 leukotriene receptor antagonists 51 entecavir 51 GRAVITAS trial 51 factorial design 51 WelChol 51 iPrEx study 51 donepezil 51 e HEALING 51 ENDEAVOR 51 pharmacodynamics PD 51 Atrasentan 51 dexamethasone Decadron 51 TriRima 51 longitudinal study 51 Phase 1b 51 metformin sulfonylurea 51 homocysteine lowering 51 bezafibrate 51 coxibs 51 sipuleucel T 51 Aggressive Reduction 51 pharmacokinetic equivalence 51 allogeneic HSCT 51 RIO Lipids 51 Tyrima 51 indacaterol 51 Subgroup analysis 51 AREDS 51 perampanel 51 OvaRex ® MAb 51 Zometa zoledronic acid 51 Endovascular Valve Edge 51 ZD# [001] 51 reboxetine 51 desvenlafaxine succinate 51 cardiac toxicity 51 CoFactor 51 heartwire 51 acute ischemic stroke 51 amrubicin 51 phase III ACCLAIM 51 F FDG PET 51 hormonal therapy 51 clopidogrel pretreatment 51 ginkgo biloba extract 51 statin drugs 51 MIRCERA 51 Dr. Kandzari 51 chemotherapy regimens 51 N acetylcysteine 51 gadobutrol 51 complete remissions 51 angiotensin receptor blockers 51 postoperative chemotherapy 51 APTIVUS ritonavir 51 adjuvant therapies 51 radical nephrectomy 51 mcg doses 51 HYVET 51 dipyridamole plus 51 fosbretabulin 51 tremelimumab 51 brivaracetam 51 acting beta agonists 51 Truvada tablets 51 fluoxetine Prozac 51 RE SURGE 51 pimecrolimus cream 51 virologic failure 51 Pivotal Trial 51 thiazolidinedione 51 raloxifene 51 minocycline 51 Hydroxyurea 51 varespladib 51 routine episiotomy 51 colesevelam HCl 51 sentinel node biopsy 51 oral anticoagulation 51 hemoglobin A1c levels 51 YONDELIS 51 Teriflunomide 51 radiographic outcomes 51 Welchol 51 EVIZON 51 Phase IIa 51 Zavesca R 51 degarelix 51 recurrent glioblastoma multiforme 51 exemestane Aromasin 51 QLT# 51 rasagiline 51 bisphosphonate 51 Vidaza azacitidine 51 ERSPC 51 EOquin TM 51 unblinding 51 EMPHASIS HF trial 51 bevacizumab 51 Wisconsin Sleep Cohort 51 lowering LDL cholesterol 51 Combo Stent 51 prospective multicenter study 51 immunomodulatory therapy 51 Phase Ia 51 primary hypercholesterolemia 51 OLYMPIA registry 51 Trandolapril 51 renal transplantation 51 Dacogen injection 51 BR.# study 51 GOUT 51 ZOLINZA 51 inhaled corticosteroid therapy 51 dose dose escalation 51 CA4P 51 TEMSO 51 registrational

Back to home page